A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.
Ontology highlight
ABSTRACT: T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-Tcells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment. However, the activity of tumor infiltrating T-cells (TILs) can be effectively neutralized in the tumor microenvironment (TME) of most solid tumors, rich in various immunosuppressive factors and cells. Therefore, to improve the clinical outcomes of established T-cell-based immunotherapy, adjuvants that can comprehensively relieve multiple immunosuppressive mechanisms of TME are needed. In this regard, recent studies have revealed that metformin has several beneficial effects on anti-tumor immunity. In this mini-review, we understand the immunosuppressive p
SUBMITTER: Kim K
PROVIDER: S-EPMC7607149 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA